Joseph focuses on corporate finance and mergers and acquisitions. He advises public and private companies and financial institutions. Joseph has extensive expertise in advising on domestic and cross border transactions, including public offerings, takeover and issuer bids, private equity and venture capital financings, private and public mergers and acquisitions, and as independent counsel to boards of directors. He has recently advised AbCellera, Zymeworks, Xenon, enGene, NervGen, Orpyx, Eupraxia, Alpha-9, Notch, adMare BioInnovations and Essa Pharma. Joseph is a director emeritus of LifeSciences BC. Joseph is a former director of the Canadian Glycomics Network (National Centre of Excellence) and Genome BC, and a member of the BIOTECanada Legal Affairs Advisory Board. He is a director of Science World and a member of the Canadian Bar Association.
On June 11, 2018, Zymeworks Inc. (Zymeworks) closed its underwritten public offering of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.
On August 14, 2018, Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) completed its June-announced acquisition of Anandia Laboratories Inc. in an all-stock transaction valued at $118 million pursuant to a court ordered plan of arrangement.
On May 3, 2017, Zymeworks Inc. completed its initial public offering (the Offering) of 4,500,000 common shares at an initial offering price of US$13.00 per share.
On February 7, 2017, Trilogy International Partners Inc. (formerly Alignvest Acquisition Corporation) (TSX:AQX.A)(TSX:AQX.WT) (“Trilogy”) completed its qualifying acquisition under which Trilogy effected a business combination with Trilogy International Partners LLC by way of a court approved plan of arrangement.
On October 15, 2015, CPI Card Group Inc. (the Company) completed its initial public offering of 17,250,000 shares of common stock at US$10.00 per share, including 2,250,000 shares of common stock sold by certain existing stockholders upon the exercise in full by the underwriters of their over-allotment option.
SciVac Therapeutics Inc., formerly Levon Resources Ltd. and SciVac Ltd. closed a plan of arrangement pursuant to which SciVac completed a reverse takeover of Levon.
On April 7, 2015, Trillium Therapeutics Inc. completed its underwritten public offering of common shares and Series II non-voting convertible first preferred shares in the United States.
